{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibyov3xztuiedjufvnqn3l4wx254kjj5txmf4cevexbpcvf4nr5m4",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mj2c2ofq4vc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreic5udpt2q5sqluo64tfde7gwfo46jrqlllrgshc7ol7lh74gmoqqy"
    },
    "mimeType": "image/jpeg",
    "size": 111846
  },
  "path": "/2026/04/08/biotech-news-terns-drug-may-not-be-as-competitive-as-initially-believed/?utm_campaign=rss",
  "publishedAt": "2026-04-08T15:16:12.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Business",
    "Pharma",
    "The Readout",
    "biotechnology",
    "drug development",
    "Drug prices",
    "research"
  ],
  "textContent": "A controversial class of drugs for Duchenne, Gilead's M&A streak, and more biotech news from The Readout",
  "title": "STAT+: Terns’ drug may not be as competitive as many initially thought",
  "updatedAt": "2026-04-08T15:16:17.000Z"
}